For example, VEGFR1 and Tie2 on tumor ECs may become “alternative” RTKs for anti-VEGF treatment, because we found ~10% human tumor EC-like cell subpopulations had 41,000 VEGFR1 and ~8% had 65,700 Tie2 on the plasma membrane. This evidence concerns the gene FLT1 and neoplasm.